The deubiquitinase BAP1 and E3 ligase UBE3C sequentially target IRF3 to activate and resolve the antiviral innate immune response
Article in Cell Reports (August 2024)
The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.
The emerging role and therapeutic implications of bacterial and parasitic deubiquitinating enzymes
Article in Frontiers in Immunology (November 2023)
The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING
Article in Science Signaling (May 2023)